Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.30 (¥3,920)-3.11%▼ (in JPY terms)
SoftBank|$30.52 (¥4,924)-6.42%▼ (in JPY terms)
MUFG|$22.83 (¥3,684)-0.43%▼ (in JPY terms)
Keyence|$483.58 (¥78,020)-5.18%▼ (in JPY terms)
Nintendo|$54.67 (¥8,821)-3.10%▼ (in JPY terms)
NTT|$1.09 (¥175)-0.23%▼ (in JPY terms)
Takeda|$36.10 (¥5,824)-0.36%▼ (in JPY terms)
Tokyo Electron|$329.19 (¥53,110)-3.40%▼ (in JPY terms)
Recruit|$101.37 (¥16,355)-6.52%▼ (in JPY terms)
ITOCHU|$13.37 (¥2,157)+0.40%▲ (in JPY terms)
Honda|$10.49 (¥1,692)-2.37%▼ (in JPY terms)
Shin-Etsu|$36.38 (¥5,870)-1.64%▼ (in JPY terms)
Tokio Marine|$48.19 (¥7,775)-0.40%▼ (in JPY terms)
Fast Retailing|$436.35 (¥70,400)-1.21%▼ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.30 (¥3,920)-3.11%▼ (in JPY terms)
SoftBank|$30.52 (¥4,924)-6.42%▼ (in JPY terms)
MUFG|$22.83 (¥3,684)-0.43%▼ (in JPY terms)
Keyence|$483.58 (¥78,020)-5.18%▼ (in JPY terms)
Nintendo|$54.67 (¥8,821)-3.10%▼ (in JPY terms)
NTT|$1.09 (¥175)-0.23%▼ (in JPY terms)
Takeda|$36.10 (¥5,824)-0.36%▼ (in JPY terms)
Tokyo Electron|$329.19 (¥53,110)-3.40%▼ (in JPY terms)
Recruit|$101.37 (¥16,355)-6.52%▼ (in JPY terms)
ITOCHU|$13.37 (¥2,157)+0.40%▲ (in JPY terms)
Honda|$10.49 (¥1,692)-2.37%▼ (in JPY terms)
Shin-Etsu|$36.38 (¥5,870)-1.64%▼ (in JPY terms)
Tokio Marine|$48.19 (¥7,775)-0.40%▼ (in JPY terms)
Fast Retailing|$436.35 (¥70,400)-1.21%▼ (in JPY terms)

Otsuka Holdings Co.,Ltd.

2026-08-28 Otsuka Holdings Co.,Ltd. “Otsuka Holdings and Sojitz have signed a virtual PPA with a special purpose company they established – promoting carbon neutrality initiatives through the expansion of "self-generated renewable energy."”

by

2026-08-28 Otsuka Holdings Co.,Ltd. “Otsuka Holdings and Sojitz have signed a virtual PPA with a special … 続きを読む

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”

by

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial … 続きを読む

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”

by

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial … 続きを読む

2026-08-13 Otsuka Holdings Co.,Ltd. “In an interim analysis of the Phase III REZILIENT3 trial in the group receiving diparereltinib in combination with chemotherapy for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the primary endpoint of progression-free survival was achieved.”

by

2026-08-13 Otsuka Holdings Co.,Ltd. “In an interim analysis of the Phase III REZILIENT3 trial in the gro … 続きを読む

2026-08-04 Otsuka Holdings Co.,Ltd. “VOYXACT® (sibeprenelimab), a treatment for IgA nephropathy, has released 2-year eGFR (estimated glomerular filtration rate) data from a Phase 3 trial – demonstrating the potential to stabilize the rate of kidney function decline within the age-appropriate range and fundamentally alter disease progression.”

by

2026-08-04 Otsuka Holdings Co.,Ltd. “VOYXACT® (sibeprenelimab), a treatment for IgA nephropathy, has rel … 続きを読む

2026-08-03 Otsuka Holdings Co.,Ltd. “Fujifilm and Taiho Pharmaceutical have entered into a strategic partnership to develop next-generation antibody-drug conjugate (ADC) manufacturing technology. The goal is to achieve stable production of high-quality ADCs by optimizing the manufacturing process.”

by

2026-08-03 Otsuka Holdings Co.,Ltd. “Fujifilm and Taiho Pharmaceutical have entered into a strategic par … 続きを読む

Contact